PUBLIC COMPANY
saveAL-S Pharma AG
founded 2016 · 30 employees · Schlieren, Zurich, CHupdated 2mo ago
AL-S Pharma is a Swiss biopharmaceutical company developing AP-101, a first-in-class human-derived monoclonal antibody targeting misfolded superoxide dismutase 1 (SOD1) for the treatment of amyotrophic lateral sclerosis. The single-asset company was founded by Neurimmune and TVM Capital Life Science and recently reported positive Phase 2 results supporting a confirmatory Phase 3 study.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.biospace · 8d ago
comments(0)
5-min edit window · permanent after that